1. Home
  2. CTRM vs BTAI Comparison

CTRM vs BTAI Comparison

Compare CTRM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.44

Market Cap

21.6M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
BTAI
Founded
2016
2017
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
24.8M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
CTRM
BTAI
Price
$2.44
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
34.1K
722.3K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.74
52 Week High
$2.65
$5.25

Technical Indicators

Market Signals
Indicator
CTRM
BTAI
Relative Strength Index (RSI) 70.02 42.92
Support Level $2.01 $0.74
Resistance Level $2.65 $1.22
Average True Range (ATR) 0.12 0.09
MACD 0.04 -0.01
Stochastic Oscillator 100.00 7.65

Price Performance

Historical Comparison
CTRM
BTAI

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: